問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

張端瑩
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

155Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張端瑩

List

262Cases

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-12-01 - 2027-03-31

Phase II

Active
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination With Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

  • Condition/Disease

    Unresectable Metastatic Colorectal Cancer

  • Test Drug

    N/A N/A N/A N/A N/A

Participate Sites
6Sites

Recruiting6Sites

2024-11-01 - 2029-08-31

Phase III

Active
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting10Sites

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-05-01 - 2028-07-31

Phase II

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)

  • Condition/Disease

    Metastatic colorectal cancer (mCRC)

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Recruiting6Sites

2020-07-01 - 2027-07-31

Phase I

Active
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-151

Participate Sites
6Sites

Recruiting6Sites

2025-06-25 - 2030-03-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

  • Condition/Disease

    ctDNA-positive colorectal cancer (CRC)

  • Test Drug

    ABBV-400

Participate Sites
3Sites

Recruiting3Sites

2019-01-08 - 2020-09-30

Phase I

Completed
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

  • Condition/Disease

    Relapsed and/or Refractory Solid Tumors

  • Test Drug

    ABBV-155

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2020-04-20 - 2024-11-01

Phase I

Completed
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-927 、ABBV-368、Budigalimab (ABBV-181)

Participate Sites
2Sites

Recruiting2Sites

2021-09-22 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

1 4 5 6 7 8 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB